Skip to content

002873.SZ

Guiyang Xintian Pharmaceutical Co., Ltd.

SZSE · Healthcare · C 制造业 · CN

CNY 8.39
−0.59%
Ask drillr

Year over year

Reported trailing growth

Revenue
-15.8%
EBITDA
EBIT
-78.8%
EPS
-80.9%
Free cash flow
+112.2%
Operating cash flow
+33.4%

Forward estimates

Based on analyst estimates

Revenue
EBITDA
EPS

Three-year CAGR

Revenue
-11.7%
EBITDA
-30.4%
EBIT
-56.4%
Net income
-56.6%
EPS
-56.8%
Free cash flow
+20.5%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026